


Sierra Leone

Region: West Africa

Key information on co-financing

- Gross National Income per capita (2017): \$ 510
- Co-financing status (2019): Initial self-financing
- Country is projected to stay in initial self financing phase for next 5 years.




Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 322,000	\$ 360,000	\$ -	\$ 430,985	\$ 372,451
- Total expenditure	\$ 4,985,272	\$ 5,070,999	\$ 5,163,865	\$ 6,288,812	\$ 4,513,746
- Government as % of total	6%	7%	0%	7%	8%
Routine immunisation					
- Government expenditure	\$ 459,907	\$ 1,395,039	\$ 1,732,842	\$ 430,985	\$ 494,492
- Total expenditure	\$ 5,283,362	\$ 6,466,038	\$ 6,896,707	\$ 9,995,653	\$ 6,970,741
- Government as % of total	9%	22%	25%	4%	7%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **1.9%**

Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Yellow Fever	Routine	2002-present	Yes
HPV	Demonstration	2013	No
Pentavalent	Routine	2007-present	Yes
PCV	Routine	2011-present	Yes
Rotavirus	Routine	2014-present	Yes
Measles	Routine	2015-present	No
IPV	Routine	2015-present	No

Co-financing payments

Year	Total amount paid by the country	Co-financed vaccines			
		Vaccine	Type	Year	Amount
2008	\$ 56,000	-	Yellow Fever	-	-
2009	\$ 54,000	-	Yellow Fever	-	-
2010	\$ 74,000	-	Yellow Fever	-	-
2011	\$ 264,000	-	Yellow Fever	PCV	-
2012	\$ 343,000	Penta	Yellow Fever	PCV	-
2013	\$ 276,000	Penta	Yellow Fever	PCV	-
2014	\$ -	Penta	Yellow Fever	PCV	Rota
2015	\$ -	Penta	Yellow Fever	PCV	Rota
2016	\$ 394,000	Penta	Yellow Fever	PCV	Rota
2017	\$ 376,700	Penta	Yellow Fever	PCV	Rota

* The 2014 and 2015 co-financing obligations were waived as part of the post-Ebola EPI Recovery Plan

Co-financing obligations for 2018

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
PCV	\$ 197,000	64,200
Pentavalent	\$ 195,000	250,500
Rota	\$ 101,500	49,500
YF	\$ 69,000	59,700
Total	\$ 562,500	


Note: country defaulted in 2018 co-financing obligations.

Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
PCV	\$ 102,000	34,200
Pentavalent	\$ 151,500	213,000
Rota	\$ 85,500	37,500
YF	\$ 75,000	61,200
HPV	\$ 53,500	11,700
MR	\$ 164,500	252,400
Total	\$ 632,000	

Note: country's HPV introduction for 2019 is on hold until country comes out of default.

Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
HPV national	\$ 36,934	\$ -	\$ 17,593	\$ 10,403	\$ 10,774
PCV	\$ 99,680	\$ 102,731	\$ 105,167	\$ 107,598	\$ 110,019
Rota	\$ 64,641	\$ 66,580	\$ 68,127	\$ 69,671	\$ 71,208
MR routine	\$ 125,165	\$ 128,663	\$ 132,163	\$ 135,664	\$ 139,156
YF routine	\$ 44,955	\$ 46,283	\$ 47,342	\$ 48,400	\$ 49,452
MR follow up	\$ -	\$ -	\$ -	\$ -	\$ 14,890
Total	\$ 371,373	\$ 344,257	\$ 370,392	\$ 371,736	\$ 395,499

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.